• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

Recent Advances in the Study of alpha,alpha-Dimethyl-beta-methylsuccinimide (CAS: 61748-86-5)

The chemical compound alpha,alpha-Dimethyl-beta-methylsuccinimide (CAS: 61748-86-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic imide derivative is structurally characterized by its dimethyl and methyl substituents on the succinimide ring, which confer unique physicochemical properties. Recent studies have explored its potential applications in drug development, particularly as a building block for novel therapeutic agents targeting neurological and metabolic disorders.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of alpha,alpha-Dimethyl-beta-methylsuccinimide as a precursor in the synthesis of gamma-aminobutyric acid (GABA) receptor modulators. The research team utilized computational docking studies to demonstrate the compound's affinity for GABA-A receptor subunits, suggesting its potential in the development of anxiolytic and anticonvulsant drugs. Experimental validation showed promising results in murine models, with derivatives of 61748-86-5 exhibiting enhanced blood-brain barrier permeability compared to traditional GABAergics.

In the area of metabolic disease research, a collaborative study between academic and industrial researchers (Nature Chemical Biology, 2024) revealed that alpha,alpha-Dimethyl-beta-methylsuccinimide derivatives can act as allosteric modulators of glucokinase. This finding opens new avenues for developing next-generation antidiabetic medications, particularly for patients with maturity-onset diabetes of the young (MODY). The unique steric properties of the 61748-86-5 scaffold were found to be crucial for maintaining the balance between enzyme activation and stability.

From a synthetic chemistry perspective, recent advancements in green chemistry protocols have improved the production efficiency of alpha,alpha-Dimethyl-beta-methylsuccinimide. A 2024 ACS Sustainable Chemistry & Engineering publication detailed a novel biocatalytic route using engineered amidases, achieving 85% yield with significantly reduced environmental impact compared to traditional synthetic methods. This development addresses previous challenges in large-scale production while maintaining the high purity required for pharmaceutical applications.

Ongoing clinical trials (Phase I/II) are currently evaluating the safety profile of 61748-86-5 derivatives in human subjects, with preliminary data suggesting good tolerability at therapeutic doses. Pharmacokinetic studies indicate that the methyl substitutions on the succinimide ring contribute to improved metabolic stability, addressing a common limitation of similar compounds. These findings position alpha,alpha-Dimethyl-beta-methylsuccinimide as a promising scaffold for further drug development efforts across multiple therapeutic areas.

• 1497-19-4(2,5-Pyrrolidinedione,3-methyl-3-propyl-)
• 77-67-8(Ethosuximide)
• 2555-05-7(3-Methyl-2-pyrrolidinone)
• 1444-94-6(octahydro-1H-isoindole-1,3-dione)
• 7506-66-3(cis-Hexahydro-1H-isoindole-1,3(2H)-dione)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)